This Article Full Text Full Text (PDF) All Versions of this Article: 200310-1405OCv1 170/10/1120    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tamm, M. Articles by Glanville, A. R. Search for Related Content PubMed PubMed Citation Articles by Tamm, M. Articles by Glanville, A. R.

Treated Cytomegalovirus Pneumonia Is Not Associated with Bronchiolitis Obliterans Syndrome

The Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia

Correspondence and requests for reprints should be addressed to Prashant N. Chhajed, D.N.B., M.D., F.C.C.P., Division of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. E-mail: pchhajed{at}uhbs.ch

The association of cytomegalovirus (CMV) infection with the development of bronchiolitis obliterans syndrome (BOS) is unclear. We studied 341 lung transplant recipients to assess whether histopathologically diagnosed CMV pneumonia treated with ganciclovir was a risk factor for development of BOS and patient survival. We also analyzed the relationship between CMV donor/recipient serologic status and BOS plus the temporal association between acute rejection and CMV pneumonia. Freedom from BOS for patients with (n = 151) and without (n = 190) CMV pneumonia was 83 and 90% (1 year), 52 and 56% (3 years), and 29 and 38% (5 years), respectively (p = 0.2660). Cumulative survival of patients with and without CMV pneumonia was 90 and 93% (1 year), 70 and 74% (3 years), and 58 and 63% (5 years), respectively (p = 0.1811). There were no significant differences in either development of BOS or patient survival with any combination of donor/recipient serostatus for CMV. Acute rejection occurred in the month preceding CMV pneumonia in 62 of 193 (32%) cases. Histopathologically confirmed CMV pneumonia treated with ganciclovir is not a risk factor for BOS or patient survival, nor is any particular CMV serologic donor/recipient group. CMV pneumonia often follows acute rejection, perhaps as a result of augmented immunosuppression.

Key Words: bronchiolitis obliterans syndrome • cytomegalovirus • lung transplant

This article has been cited by other articles:

				A. R. Glanville, C. L. Aboyoun, A. Havryk, M. Plit, S. Rainer, and M. A. Malouf Severity of Lymphocytic Bronchiolitis Predicts Long-Term Outcome after Lung Transplantation Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1033 - 1040. [Abstract] [Full Text] [PDF]

				M. J. Russo, D. I. Sternberg, K. N. Hong, R. A. Sorabella, A. J. Moskowitz, A. C. Gelijns, J. R. Wilt, F. D'Ovidio, S. M. Kawut, S. M. Arcasoy, et al. Postlung Transplant Survival is Equivalent Regardless of Cytomegalovirus Match Status Ann. Thorac. Surg., October 1, 2007; 84(4): 1129 - 1135. [Abstract] [Full Text] [PDF]

				J.-F. Cordier Challenges in pulmonary fibrosis {middle dot} 2 : Bronchiolocentric fibrosis Thorax, July 1, 2007; 62(7): 638 - 649. [Abstract] [Full Text] [PDF]

				B. Nemery, W. W. Yew, R. Albert, C. Brun-Buisson, W. MacNee, F. J. Martinez, D. C. Angus, and E. Abraham Tuberculosis, Nontuberculous Lung Infection, Pleural Disorders, Pulmonary Function, Respiratory Muscles, Occupational Lung Disease, Pulmonary Infections, and Social Issues in AJRCCM in 2004 Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 554 - 562. [Full Text] [PDF]